Ovid Therapeutics gets grant for treatment of status epilepticus with ganaxolone continuous intravenous infusion

2d ago, source: Pharmaceutical Technology

Discover Ovid Therapeutics Inc's groundbreaking patent on using ganaxolone to treat status epilepticus. Learn about the specific dosage ranges and infusion methods for sustained symptom improvement.

Ovid Therapeutics Inc

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

21d ago, source: Yahoo Finance

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies ...

Ovid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic Partnerships

1mon ago, source: Business Insider

Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on Ovid Therapeutics (OVID – Research Report), with a price target of $7.00. Michael Higgins has given his Buy rating ...

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

1mon ago, source: ADVFN

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders ...

Ovid Therapeutics Inc OVID

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

21d ago, source: Yahoo Finance

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to ...

Ovid Therapeutics Inc. (OVID)

4d ago, source: Yahoo Finance

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies ...

Ovid Therapeutics Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...